The role of radiation therapy in the treatment of stage I-II diffuse large B-cell lymphoma

Current Hematologic Malignancy Reports

Volumn 8, Issue 3, 2013, Pages 236-242

  Campbell, Belinda A ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Diffuse C20.683.515.761.480. 150.585 ; Large B Cell; Lymphoma; Lymphoma C04.557.386 ; Radiotherapy E02.815

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; PREDNISOLONE; RITUXIMAB; VINCRISTINE; VINDESINE; MONOCLONAL ANTIBODY; PREDNISONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADJUVANT CHEMORADIOTHERAPY; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CONSOLIDATION CHEMOTHERAPY; DISEASE SPECIFIC SURVIVAL; DOSIMETRY; EARLY CANCER; HIGH RISK PATIENT; HUMAN; INFECTION; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; LONG TERM SURVIVAL; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION EXPOSURE; RADIATION INJURY; RETROSPECTIVE STUDY; STAGING; SURVIVAL RATE; SYSTEMIC THERAPY; ANALOGS AND DERIVATIVES; CANCER STAGING; LYMPHOMA, LARGE B-CELL, DIFFUSE; MULTIMODAL IMAGING; PATHOLOGY; PROCEDURES;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MULTIMODAL IMAGING; NEOPLASM STAGING; PREDNISONE; VINCRISTINE;

EID: 84883895255     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-013-0170-5     Document Type: Article

References (36)

1. Swerdlow S, Campo E, Harris N et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. In Edition Lyon: IARC Press 2008.
2. Ng AK. Diffuse large B-cell lymphoma. Semin Radiat Oncol. 2007;17:169-75.
3. Persky DO, Miller TP. Localized large cell lymphoma: is there any need for radiation therapy? Curr Opin Oncol. 2009;21:401-6.
4. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer (IARC) 2008.
5. Friedberg JW, Fisher RI. Diffuse large B-cell lymphoma. Hematol Oncol Clin North Am. 2008;22:941-52. ix.
6. Zelenetz AD, Abramson JS, Advani RH, et al. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw. 2010;8:288-334.
7. Tilly H, Vitolo U, Walewski J, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii78-82.
8. Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol. 2008;26:2258-63.
9. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379-91.
10. Wirth A. The rationale and role of radiation therapy in the treatment of patients with diffuse large B-cell lymphoma in the Rituximab era. Leuk Lymphoma. 2007;48:2121-36.
11. Illidge T, Tolan S. Current treatment approaches for diffuse large B-cell lymphoma. Leuk Lymphoma. 2008;49:663-76.
12. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121-7.
13. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998;339:21-6.
14. Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med. 2005;352:1197-205.
15. Andre M, Mounier N, Leleu X, et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood. 2004;103:1222-8.
16. Bonnet C, Fillet G, Mounier N, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2007;25:787-92.
17. Horning SJ, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol. 2004;22:3032-8.
18. Kamath SS, Marcus Jr RB, Lynch JW, Mendenhall NP. The impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 1999;44:563-8.
19. Bindra RS, Yahalom J. The important role of radiation therapy in early-stage diffuse large B-cell lymphoma: time to review the evidence once again. Expert Rev Anticancer Ther. 2011;11:1367-78.
20. Ballonoff A, Rusthoven KE, Schwer A, et al. Outcomes and effect of radiotherapy in patients with stage I or II diffuse large B-cell lymphoma: a surveillance, epidemiology, and end results analysis. Int J Radiat Oncol Biol Phys. 2008;72:1465-71.
21. • Phan J, Mazloom A, Jeffrey Medeiros L, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol. 2010;28:4170-6. In multivariate and matched-pair analyses, the authors found that patients with stage I-II diffuse large B-cell lymphoma benefited from the addition of RT with significant improvements in PFS and OS.
22. Yahalom J. Radiation therapy after R-CHOP for diffuse large B-cell lymphoma: the gain remains. J Clin Oncol. 2010;28:4105-7.
23. Miller TP, Leblanc M, Spier C, et al. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: update of the Southwest Oncology Group (SWOG) randomized trial. Blood. 2001;98:742a-3.
24. Shenkier TN, Voss N, Fairey R, et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol. 2002;20:197-204.
25. • Campbell BA, Connors JM, Gascoyne RD, et al. Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy: involved-field versus involved-node radiotherapy. Cancer. 2012;118:4156-65. The authors demonstrate that the RT field size can be safely reduced, without compromising progression-free survival or overall survival rates, in patients with stage I-II diffuse large B-cell lymphoma receiving consolidation RT after abbreviated chemotherapy.
26. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-42.
27. Moskowitz CH. Interim PET-CT in the management of diffuse large B-cell lymphoma. Hematol Am Soc Hematol Educ Program. 2012;2012:397-401.
28. Cashen AF, Dehdashti F, Luo J, et al. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med. 2011;52:386-92.
29. Meignan M, Itti E, Gallamini A, Haioun C. Interim 18F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation-where do we stand? Leuk Lymphoma. 2009;50:1753-6.
30. Michallet AS, Trotman J, Tychyj-Pinel C. Role of early PET in the management of diffuse large B-cell lymphoma. Curr Opin Oncol. 2010;22:414-8.
31. Dabaja BS, Phan J, Mawlawi O et al. Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma. Leuk Lymphoma 2013.
32. Yu JI, Nam H, Ahn YC, et al. Involved-lesion radiation therapy after chemotherapy in limited-stage head-and-neck diffuse large B cell lymphoma. Int J Radiat Oncol Biol Phys. 2010;78:507-12.
33. Isobe K, Kawakami H, Tamaru J, et al. Consolidation radiotherapy following brief chemotherapy for localized diffuse large B-cell lymphoma: a prospective study. Leuk Lymphoma. 2003;44:1535-9.
34. Campbell BA, Voss N, Pickles T, et al. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size. J Clin Oncol. 2008;26:5170-4.
35. Campbell BA, Hornby C, Cunninghame J, et al. Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy. Ann Oncol. 2012;23:1259-66.
36. • Yahalom J. Modern radiotherapy for lymphomas - concepts and treatment guidelines. In Lugano, Switzerland: International Lymphoma Radiation Oncology (ILROG) 2013. International guidelines for the delivery of consolidation RT are to be presented by the International Lymphoma Radiation Oncology Group.